A generalized non-linear model predicting efficacy of neoadjuvant therapy in HER2+ breast cancer

Neoadjuvant therapy (NAT) is currently recommended to patients with human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) that typically exhibit a poor prognosis. The tumor immune microenvironment profoundly affects the efficacy of NAT. However, the correlation between tumor-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yusong, Liu, Xiaoyan, Yu, Keda, Xu, Shouping, Qiu, Pengfei, Zhang, Xinwen, Wang, Mozhi, Xu, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025957/
https://www.ncbi.nlm.nih.gov/pubmed/36950120
http://dx.doi.org/10.1016/j.isci.2023.106330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025957/
https://www.ncbi.nlm.nih.gov/pubmed/36950120
http://dx.doi.org/10.1016/j.isci.2023.106330

Ejemplares similares